News Moderna, Inc. Berne S.E.

Equities

0QF

US60770K1079

Delayed Berne S.E. Other stock markets 17:00:00 15/04/2024 BST			5-day change	1st Jan Change
96.41 ^CHF	+1.01%		-39.82%	-47.70%

07-15	Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing	MT
07-12	China approves CSPC Pharma's RSV vaccine for clinical trials	RE

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing	07-15	MT
China approves CSPC Pharma's RSV vaccine for clinical trials	07-12	RE
Flagship Pioneering Expands Leadership Team with Key Appointments and Promotions	07-11	AQ
Moderna to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024	07-11	AQ
Flagship Pioneering Raises $3.6 Billion to Fuel Breakthrough Innovations that Transform Human Health and Sustainability	07-11	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA	07-10	PR
Flagship Pioneering Raises $3.6B for 'New Wave' of Health, AI Innovation	07-10	MT
Redburn Raises Moderna's Price Target to $117 From $116	07-10	MT
Bird flu response in Michigan sparks COVID-era worry on farms	07-10	RE
Melanoma Pipeline 2024 \| IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed	07-10	AQ
Moderna and Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna's mRNA Respiratory Vaccine Portfolio in Japan, Including COVID-19 Vaccines	07-09	AQ
Moderna: partnership for mRNA vaccines in Japan	07-09	CF
Moderna Partners With Mitsubishi Tanabe Pharma to Promote Vaccines in Japan	07-09	MT
Moderna and Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna?s Mrna Respiratory Vaccine Portfolio in Japan, Including Covid-19 Vaccines	07-09	CI
HilleVax to discontinue development of norovirus vaccine for infants; shares plummet	07-08	RE
Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births	07-08	RE
The US will pay Moderna $176 million to develop an mRNA pandemic flu vaccine	07-02	AQ
Moderna, Pfizer-BioNTech COVID-19 Vaccine Patent Legal Battle Gets Mixed UK Ruling	07-02	MT
US will pay vaccine maker Moderna $176 million to develop an mRNA-based pandemic flu vaccine	07-02	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA	07-02	PR